

CITATION REPORT

List of articles citing

Gut--liver axis: the impact of gut microbiota on non alcoholic fatty liver disease

DOI: 10.1016/j.numecd.2012.02.007

Nutrition, Metabolism and Cardiovascular Diseases,
2012, 22, 471-6.

Source: <https://exaly.com/paper-pdf/53536049/citation-report.pdf>

Version: 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
308	Human serum proteome analysis: new source of markers in metabolic disorders. 2012 , 6, 759-73		19
307	Causative role of gut microbiota in non-alcoholic fatty liver disease pathogenesis. 2012 , 2, 132		36
306	The gut microbiota and the liver. Pathophysiological and clinical implications. 2013 , 58, 1020-7		85
305	Gut microbiota and non-alcoholic fatty liver disease: new insights. 2013 , 19, 338-48		157
304	Colonic bacterial metabolites and human health. 2013 , 16, 246-54		243
303	Nonalcoholic fatty liver disease: for better or worse, blame the gut microbiota?. 2013 , 37, 787-93		20
302	Probiotics in the treatment of non alcoholic fatty liver disease: further evidence in obese children. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2013 , 23, e9-10	4.5	4
301	Gut-liver axis: role of inflammasomes. 2013 , 3, 141-9		22
300	Therapeutic approaches to non-alcoholic fatty liver disease: past achievements and future challenges. 2013 , 12, 125-35		30
299	Fatty liver accompanies an increase in lactobacillus species in the hind gut of C57BL/6 mice fed a high-fat diet. 2013 , 143, 627-31		62
298	Gastrointestinal bacterial overgrowth: pathogenesis and clinical significance. 2013 , 4, 223-31		106
297	Towards polypharmacokinetics: pharmacokinetics of multicomponent drugs and herbal medicines using a metabolomics approach. 2013 , 2013, 819147		32
296	What does irritable bowel syndrome share with non-alcoholic fatty liver disease?. 2013 , 19, 5402-20		15
295	Pathophysiology of NASH: perspectives for a targeted treatment. 2013 , 19, 5250-69		110
294	Probiotic as a novel treatment strategy against liver disease. 2013 , 13, e7521		45
293	Probiotics in non-alcoholic fatty liver disease: which and when. 2013 , 12, 357-363		27
292	Probiotics and liver disease. 2013 , 17, 62-7		29

291	Increased circulating zonulin in children with biopsy-proven nonalcoholic fatty liver disease. 2014 , 20, 17107-14	38
290	Recent advances in dietary supplementation, in treating non-alcoholic fatty liver disease. 2015 , 7, 204-12	50
289	Gut microbiota in alcoholic liver disease: pathogenetic role and therapeutic perspectives. 2014 , 20, 16639-48	90
288	Gut-liver axis and probiotics: their role in non-alcoholic fatty liver disease. 2014 , 20, 15518-31	111
287	Non-alcoholic fatty liver disease in obese adults: clinical aspects and current management strategies. 2014 , 4, 243-53	20
286	An alteration of the gut-liver axis drives pulmonary inflammation after intoxication and burn injury in mice. 2014 , 307, G711-8	22
285	Meta-omic platforms to assist in the understanding of NAFLD gut microbiota alterations: tools and applications. 2014 , 15, 684-711	21
284	Randomised clinical trial: The beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis. 2014 , 39, 1276-85	269
283	Probiotics to Treat Visceral Obesity and Related Liver Disease. 2014 , 363-380	1
282	Contributions of metabolic dysregulation and inflammation to nonalcoholic steatohepatitis, hepatic fibrosis, and cancer. 2014 , 26, 100-7	65
281	Mediterranean diet and health: food effects on gut microbiota and disease control. 2014 , 15, 11678-99	107
280	Nonalcoholic fatty liver disease and bariatric surgery in adolescents. 2014 , 23, 49-57	18
279	Rational identification of diet-derived postbiotics for improving intestinal microbiota function. 2014 , 26, 85-90	41
278	Gut microbiota and liver disease. 2014 , 29, 1139-48	70
277	Hepatic molecular responses to Bifidobacterium pseudocatenulatum CECT 7765 in a mouse model of diet-induced obesity. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , 2014 , 24, 57-64	4.5 26
276	Boom of probiotics: This time non-alcoholic fatty liver disease I A mini review. 2014 , 11, 30-35	9
275	Precision-cut liver slices from diet-induced obese rats exposed to ethanol are susceptible to oxidative stress and increased fatty acid synthesis. 2014 , 306, G208-17	12
274	The gut-adipose-liver axis in the metabolic syndrome. 2014 , 29, 304-13	47

273	Synbiotic supplementation in nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled pilot study. 2014 , 99, 535-42	226
272	Effects of synbiotic supplementation on insulin resistance in subjects with the metabolic syndrome: a randomised, double-blind, placebo-controlled pilot study. 2014 , 112, 438-45	80
271	Review article: the management of paediatric nonalcoholic fatty liver disease. 2014 , 40, 1155-70	33
270	Systematic review: microbial dysbiosis and nonalcoholic fatty liver disease. 2015 , 42, 1051-63	122
269	The Gut Microbiota, Intestinal Permeability, Bacterial Translocation, and Nonalcoholic Fatty Liver Disease: What Comes First?. 2015 , 1, 129-130	2
268	Non-alcoholic fatty liver disease as a consequence of autonomic imbalance and circadian desynchronization. 2015 , 16, 871-82	15
267	Liver involvement in pediatric celiac disease. 2015 , 21, 5813-22	36
266	Oxidative Stress and Inflammation in Hepatic Diseases: Therapeutic Possibilities of N-Acetylcysteine. 2015 , 16, 30269-308	132
265	Gut Microbiota: Association with NAFLD and Metabolic Disturbances. 2015 , 2015, 979515	44
264	PATHOGENESIS OF HEPATOCELLULAR CARCINOMA DEVELOPMENT IN NON ALCOHOLIC FATTY LIVER DISEASE. 2015 , 14, 119-127	14
263	Metagenomic and metabolomic analysis of the toxic effects of trichloroacetamide-induced gut microbiome and urine metabolome perturbations in mice. 2015 , 14, 1752-61	45
262	Dysbiosis gut microbiota associated with inflammation and impaired mucosal immune function in intestine of humans with non-alcoholic fatty liver disease. 2015 , 5, 8096	311
261	Nonalcoholic fatty liver disease (NAFLD) without insulin resistance: Is it different?. 2015 , 39, 482-8	19
260	Mikrobiom zwischen Intestinum und Leber. 2015 , 10, 111-115	
259	Gut permeability, its interaction with gut microflora and effects on metabolic health are mediated by the lymphatics system, liver and bile acid. 2015 , 10, 1339-53	31
258	The Riddle of Nonalcoholic Fatty Liver Disease: Progression From Nonalcoholic Fatty Liver to Nonalcoholic Steatohepatitis. 2015 , 5, 147-58	81
257	Lactobacillus paracasei Induces M2-Dominant Kupffer Cell Polarization in a Mouse Model of Nonalcoholic Steatohepatitis. 2015 , 60, 3340-50	34
256	Role of Microbiota in Regulating Host Lipid Metabolism and Disease Risk. 2015 , 235-260	1

255	Impacts of gut bacteria on human health and diseases. 2015 , 16, 7493-519	420
254	Effects of Mediterranean diet supplemented with silybin-vitamin E-phospholipid complex in overweight patients with non-alcoholic fatty liver disease. 2015 , 9, 519-27	63
253	Urinary (1)H-NMR-based metabolic profiling of children with NAFLD undergoing VSL#3 treatment. 2015 , 39, 1118-25	43
252	Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease. 2015 , 30, 780-6	27
251	Liver sinusoidal endothelial cells (LSECs) function and NAFLD; NO-based therapy targeted to the liver. 2015 , 67, 689-94	59
250	Reduced Lysosomal Acid Lipase Activity in Adult Patients With Non-alcoholic Fatty Liver Disease. 2015 , 2, 750-4	41
249	Hepatoprotective Effects of Chinese Medicinal Herbs: A Focus on Anti-Inflammatory and Anti-Oxidative Activities. 2016 , 17, 465	72
248	The Metabolic Role of Gut Microbiota in the Development of Nonalcoholic Fatty Liver Disease and Cardiovascular Disease. 2016 , 17,	42
247	The Gut Bacteria-Driven Obesity Development. 2016 , 34, 221-9	41
246	Dietary nucleotides protect against alcoholic liver injury by attenuating inflammation and regulating gut microbiota in rats. 2016 , 7, 2898-908	17
245	Treatment with Oxidized Phospholipids Directly Inhibits Nonalcoholic Steatohepatitis and Liver Fibrosis Without Affecting Steatosis. 2016 , 61, 2545-53	12
244	Foodomics as part of the host-microbiota-exposome interplay. 2016 , 147, 3-20	37
243	Alcohol and lung injury and immunity. 2016 , 55, 51-59	46
242	Gut epithelial barrier markers in patients with obstructive sleep apnea. 2016 , 26, 12-15	19
241	Hypogonadism alters cecal and fecal microbiota in male mice. 2016 , 7, 533-539	33
240	The effects of synbiotic supplementation on markers of insulin metabolism and lipid profiles in gestational diabetes: a randomised, double-blind, placebo-controlled trial. 2016 , 116, 1394-1401	37
239	Impact of Dietary Fibers on Nutrient Management and Detoxification Organs: Gut, Liver, and Kidneys. 2016 , 7, 1111-1121	30
238	Enterogenous bacterial glycolipids are required for the generation of natural killer T cells mediated liver injury. 2016 , 6, 36365	24

237	Soy and Gut Microbiota: Interaction and Implication for Human Health. 2016 , 64, 8695-8709	70
236	The role of the gut microbiota in NAFLD. 2016 , 13, 412-25	459
235	Liver fibrosis and fatty liver in Asian HIV-infected patients. 2016 , 44, 411-21	35
234	Obesity, Asthma, and the Microbiome. 2016 , 31, 108-16	22
233	Metagenomic Analysis Reveals Dynamic Changes of Whole Gut Microbiota in the Acute Phase of Intensive Care Unit Patients. 2016 , 61, 1628-34	107
232	Microbiota, immunity and the liver. 2016 , 171, 36-49	14
231	Gut Microbiota of Nonalcoholic Fatty Liver Disease. 2016 , 61, 1268-81	37
230	Effects of Multistrain Probiotic Supplementation on Glycemic and Inflammatory Indices in Patients with Nonalcoholic Fatty Liver Disease: A Double-Blind Randomized Clinical Trial. 2016 , 35, 500-505	50
229	SIV-induced Translocation of Bacterial Products in the Liver Mobilizes Myeloid Dendritic and Natural Killer Cells Associated With Liver Damage. 2016 , 213, 361-9	21
228	Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated meta-omics-based approach. 2017 , 65, 451-464	354
227	Alcohol Modulation of the Postburn Hepatic Response. 2017 , 38, e144-e157	5
226	Therapies in non-alcoholic steatohepatitis (NASH). 2017 , 37 Suppl 1, 97-103	129
225	Clostridium butyricum B1 alleviates high-fat diet-induced steatohepatitis in mice via enterohepatic immunoregulation. 2017 , 32, 1640-1648	22
224	Low-Dose Therapy for the Treatment of Low-Grade Chronic Inflammation. 2017 , 27-38	1
223	Kefir alleviates obesity and hepatic steatosis in high-fat diet-fed mice by modulation of gut microbiota and mycobiota: targeted and untargeted community analysis with correlation of biomarkers. 2017 , 44, 35-43	93
222	Influence of diet on the gut microbiome and implications for human health. 2017 , 15, 73	983
221	Evaluation of circulating zonulin as a potential marker in the pathogenesis of nonalcoholic fatty liver disease. 2017 , 125, 607-613	23
220	Frequency and Risk Factors of Clostridium difficile Infection in Hospitalized Patients With Pouchitis: A Population-based Study. 2017 , 23, 661-671	15

219	Utilization of defined microbial communities enables effective evaluation of meta-genomic assemblies. 2017 , 18, 296	18
218	Synbiotic supplementation and the effects on clinical and metabolic responses in patients with rheumatoid arthritis: a randomised, double-blind, placebo-controlled trial. 2017 , 117, 1095-1102	39
217	Total fecal microbiota transplantation alleviates high-fat diet-induced steatohepatitis in mice via beneficial regulation of gut microbiota. 2017 , 7, 1529	163
216	Saccharomyces boulardii Administration Changes Gut Microbiota and Attenuates D-Galactosamine-Induced Liver Injury. 2017 , 7, 1359	32
215	The gut microbiota: A new potential driving force in liver cirrhosis and hepatocellular carcinoma. 2017 , 5, 944-953	33
214	Microbiome and NAFLD: potential influence of aerobic fitness and lifestyle modification. 2017 , 49, 385-399	18
213	Synbiotic supplementation in lean patients with non-alcoholic fatty liver disease: a pilot, randomised, double-blind, placebo-controlled, clinical trial. 2017 , 117, 662-668	107
212	Probiotics may delay the progression of nonalcoholic fatty liver disease by restoring the gut microbiota structure and improving intestinal endotoxemia. 2017 , 7, 45176	131
211	Nonalcoholic Fatty Liver Disease, the Gut Microbiome, and Diet. 2017 , 8, 240-252	85
210	Orally Administered Berberine Modulates Hepatic Lipid Metabolism by Altering Microbial Bile Acid Metabolism and the Intestinal FXR Signaling Pathway. 2017 , 91, 110-122	94
209	Gut microbiota dysbiosis in patients with non-alcoholic fatty liver disease. 2017 , 16, 375-381	217
208	The pharmacological management of NAFLD in children and adolescents. 2017 , 10, 1225-1237	9
207	Exploring the microbiome in health and disease: Implications for toxicology. 2017 , 1, 239784731774188	19
206	Dietary Impacts on the Composition of Microbiota in Human Health and Disease. 2017 , 377-404	
205	Preventing subclinical necrotic enteritis through Lactobacillus johnsonii BS15 by ameliorating lipid metabolism and intestinal microflora in broiler chickens. 2017 , 7, 139	30
204	Intestinal gas and liver steatosis: a casual association? A prospective multicentre assessment. 2017 , 37, 141-147	0
203	Crosstalk between the gut and the liver via susceptibility loci: Novel advances in inflammatory bowel disease and autoimmune liver disease. 2017 , 175, 115-123	7
202	Role of Probiotics in the Treatment of Nonalcoholic Fatty Liver Disease: A Meta-analysis. 2017 , 7, 130-137	33

201	Fructose and NAFLD: The Multifaceted Aspects of Fructose Metabolism. 2017 , 9,	107
200	Enhanced offspring predisposition to steatohepatitis with maternal high-fat diet is associated with epigenetic and microbiome alterations. 2017 , 12, e0175675	94
199	Effects of Probiotic and Prebiotic Supplementation on Leptin, Adiponectin, and Glycemic Parameters in Non-alcoholic Fatty Liver Disease: A Randomized Clinical Trial. 2017 , 9, 150-157	43
198	Gut : liver : brain axis: the microbial challenge in the hepatic encephalopathy. 2018 , 9, 1373-1388	35
197	NAFLD and HIV: Do Sex, Race, and Ethnicity Explain HIV-Related Risk?. 2018 , 15, 212-222	5
196	The effects of synbiotic supplementation on hormonal status, biomarkers of inflammation and oxidative stress in subjects with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. 2018 , 18, 21	29
195	Practical Dietary Recommendations for the Prevention and Management of Nonalcoholic Fatty Liver Disease in Adults. 2018 , 9, 30-40	46
194	Polystyrene microplastics induce gut microbiota dysbiosis and hepatic lipid metabolism disorder in mice. 2018 , 631-632, 449-458	281
193	Non-alcoholic fatty liver disease and its treatment with n-3 polyunsaturated fatty acids. 2018 , 37, 37-55	66
192	New insight into inter-organ crosstalk contributing to the pathogenesis of non-alcoholic fatty liver disease (NAFLD). 2018 , 9, 164-177	61
191	Environmental peer pressure: CD4 T cell help in tolerance and transplantation. 2018 , 24, 89-97	5
190	The gut-liver axis: impact of a mouse model of small-bowel bacterial overgrowth. 2018 , 221, 246-256	3
189	Vitamin A deficiency in mice alters host and gut microbial metabolism leading to altered energy homeostasis. 2018 , 54, 28-34	39
188	Gegen Qinlian Decoction Attenuates High-Fat Diet-Induced Steatohepatitis in Rats via Gut Microbiota. 2018 , 2018, 7370891	17
187	Metformin ameliorated methotrexate-induced hepatorenal toxicity in rats in addition to its antitumor activity: two birds with one stone. 2018 , 11, 421-429	7
186	An overview on the interplay between nutraceuticals and gut microbiota. 2018 , 6, e4465	17
185	Gut microbiota translocation promotes autoimmune cholangitis. 2018 , 95, 47-57	27
184	Modulation of gut microbiome in nonalcoholic fatty liver disease: pro-, pre-, syn-, and antibiotics. 2018 , 56, 855-867	21

183	Nutrition and Lifestyle Modifications in the Prevention and Treatment of Non-Alcoholic Fatty Liver Disease. 2018 ,	0
182	Functional Relationship Between the Gut and Other Tissues/Organs of the Body. 2018 , 1009-1028	
181	Daily Consumption of Synbiotic Yogurt Decreases Liver Steatosis in Patients with Nonalcoholic Fatty Liver Disease: A Randomized Controlled Clinical Trial. 2018 , 148, 1276-1284	54
180	Gut Microbes: The Miniscule Laborers in the Human Body. 2018 , 1-31	1
179	Targeting gut microbiota in hepatocellular carcinoma: probiotics as a novel therapy. 2018 , 7, 11-20	52
178	Intestinal Microbiome Shifts, Dysbiosis, Inflammation, and Non-alcoholic Fatty Liver Disease. 2018 , 9, 61	83
177	New Aspects of Lipotoxicity in Nonalcoholic Steatohepatitis. 2018 , 19,	72
176	Variation in the Plasma Levels of Polyunsaturated Fatty Acids in Control vis-à-vis Nonalcoholic Fatty Liver Disease Subjects and Its Possible Association with Gut Microbiome. 2018 , 16, 329-335	2
175	Clinical, anthropometric, biochemical and histological character of nonalcoholic fatty liver disease without Insulin Resistance. 2019 , 9, 176-181	5
174	Effect of Kombucha on gut-microbiota in mouse having non-alcoholic fatty liver disease. 2019 , 28, 261-267	22
173	Role and effective therapeutic target of gut microbiota in NAFLD/NASH. 2019 , 18, 1935-1944	13
172	Fatty Liver Disease and Gut Microbiota: A Comprehensive Update. 2019 , 7, 56-60	28
171	Probiotics for dietary management of non-alcoholic fatty liver disease. 2019 , 17, 1553-1563	8
170	Aged garlic extract ameliorates fatty liver and insulin resistance and improves the gut microbiota profile in a mouse model of insulin resistance. 2019 , 18, 857-866	11
169	Diet Consisting of Balanced Yogurt, Fruit, and Vegetables Modifies the Gut Microbiota and Protects Mice against Nonalcoholic Fatty Liver Disease. 2019 , 63, e1900249	10
168	Serum Zonulin in HBV-Associated Chronic Hepatitis, Liver Cirrhosis, and Hepatocellular Carcinoma. 2019 , 2019, 5945721	10
167	Involvement of TLR4/ CXCL9/ PREX-2 pathway in the development of hepatocellular carcinoma (HCC) and the promising role of early administration of lactobacillus plantarum in Wistar rats. 2019 , 60, 38-47	8
166	Plasma diamine oxidase level predicts 6-month readmission for patients with hepatitis B virus-related decompensated cirrhosis. 2019 , 16, 115	1

165	The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD). 2019 , 76, 1541-1558	161
164	Animal Models for Human Polycystic Ovary Syndrome (PCOS) Focused on the Use of Indirect Hormonal Perturbations: A Review of the Literature. 2019 , 20,	18
163	Yogurt improves insulin resistance and liver fat in obese women with nonalcoholic fatty liver disease and metabolic syndrome: a randomized controlled trial. 2019 , 109, 1611-1619	34
162	SC06 Protects Mice Against High-Fat Diet-Induced Obesity and Liver Injury via Regulating Host Metabolism and Gut Microbiota. 2019 , 10, 1161	25
161	Lactobacillus plantarum NA136 improves the non-alcoholic fatty liver disease by modulating the AMPK/Nrf2 pathway. 2019 , 103, 5843-5850	31
160	Linderae radix ethanol extract attenuates alcoholic liver injury via attenuating inflammation and regulating gut microbiota in rats. 2019 , 52, e7628	11
159	Sphingosine-1-phosphate signaling and the gut-liver axis in liver diseases. 2019 , 3, 19-24	6
158	The role of gut microbiota in liver disease development and treatment. 2019 , 3, 3-18	24
157	The role of sphingosine kinase 2 in alcoholic liver disease. 2019 , 51, 1154-1163	15
156	The Gut Microbiome Signatures Discriminate Healthy From Pulmonary Tuberculosis Patients. 2019 , 9, 90	52
155	Potential Link between Gut Microbiota and Deoxynivalenol-Induced Feed Refusal in Weaned Piglets. 2019 , 67, 4976-4986	18
154	What are the main areas of focus to prevent or treat non-alcoholic fatty liver disease?. 2019 , 20, 271-277	2
153	The Effects of Vegetarian and Vegan Diets on Gut Microbiota. 2019 , 6, 47	178
152	Role of the intestinal microbiome in liver fibrosis development and new treatment strategies. 2019 , 209, 22-38	18
151	Intestinal Barrier Function-Non-alcoholic Fatty Liver Disease Interactions and Possible Role of Gut Microbiota. 2019 , 67, 2754-2762	64
150	Gut Microbes in Liver Diseases: Dietary Intervention for Promoting Hepatic Health. 2019 , 117-131	
149	Dietary wheat amylase trypsin inhibitors promote features of murine non-alcoholic fatty liver disease. 2019 , 9, 17463	12
148	The Metabolic Response to Ozone. 2019 , 10, 2890	6

147	The promising role of probiotic and synbiotic therapy in aminotransferase levels and inflammatory markers in patients with nonalcoholic fatty liver disease - a systematic review and meta-analysis. 2019 , 31, 703-715	9
146	PPAR γ inhibition protects against palmitic acid-LPS induced lipidosis and injury in cultured hepatocyte L02 cell. 2019 , 16, 1593-1603	10
145	Gut microbiota: novel therapeutic target for nonalcoholic fatty liver disease. 2019 , 13, 193-204	39
144	Inflammatory gene expression analysis after prebiotic, probiotic and synbiotic supplementation in experimental nonalcoholic fatty liver disease. 2019 , 49, 75-84	3
143	Transcriptome analysis of grass carp provides insights into disease-related genes and novel regulation pattern of bile acid feedback in response to lithocholic acid. 2019 , 500, 613-621	5
142	Advancing the understanding of NAFLD to hepatocellular carcinoma development: From experimental models to humans. 2019 , 1871, 117-125	33
141	The Effects of Synbiotic Supplementation on Metabolic Status in Women With Polycystic Ovary Syndrome: a Randomized Double-Blind Clinical Trial. 2019 , 11, 1355-1361	22
140	High dosages of pectin and cellulose cause different degrees of damage to the livers and intestines of <i>Pelteobagrus fulvidraco</i> . 2020 , 514, 734445	10
139	Alterations of endogenous sphingolipid metabolism in cardiometabolic diseases: Towards novel therapeutic approaches. 2020 , 169, 133-143	10
138	Gut microbiota dysbiosis in patients with hepatitis B virus-induced chronic liver disease covering chronic hepatitis, liver cirrhosis and hepatocellular carcinoma. 2020 , 27, 143-155	42
137	Gut microbiota: A new piece in understanding hepatocarcinogenesis. 2020 , 474, 15-22	15
136	Absence of the Caspases 1/11 Modulates Liver Global Lipid Profile and Gut Microbiota in High-Fat-Diet-Induced Obese Mice. 2019 , 10, 2926	6
135	Ablation of in Intestinal Epithelial Cells Causes Intestinal Lipid Accumulation and Reduces NASH in Mice. 2020 , 4, 92-108	4
134	Macrophage Polarization Induced by Probiotic Bacteria: a Concise Review. 2020 , 12, 798-808	10
133	Increased Liver Localization of Lipopolysaccharides in Human and Experimental NAFLD. 2020 , 72, 470-485	90
132	Characterization of the Nutritional Composition of a Biotechnologically Produced Oyster Mushroom and its Physiological Effects in Obese Zucker Rats. 2020 , 64, e2000591	4
131	Fermented Feed Supplement Relieves Caecal Microbiota Dysbiosis and Kidney Injury Caused by High-Protein Diet in the Development of Gosling Gout. 2020 , 10,	5
130	Effective Combination Therapy of Angiotensin-II Receptor Blocker and Rifaximin for Hepatic Fibrosis in Rat Model of Nonalcoholic Steatohepatitis. 2020 , 21,	8

129	Effects of synbiotic supplementation on the components of metabolic syndrome in military personnel: a double-blind randomised controlled trial. 2020 ,	5
128	A longitudinal study reveals the alterations of the <i>Microtus fortis</i> colonic microbiota during the natural resistance to <i>Schistosoma japonicum</i> infection. 2020 , 219, 108030	0
127	Effects of probiotic and prebiotic supplementation on metabolic parameters, liver aminotransferases, and systemic inflammation in nonalcoholic fatty liver disease: A randomized clinical trial. 2020 , 85, 3611-3617	13
126	Three-tissue microphysiological system for studying inflammatory responses in gut-liver Axis. 2020 , 22, 65	5
125	GC-TOF-MS-Based Metabolomics Analyses of Liver and Intestinal Contents in the Overfed vs. Normally-Fed Geese. 2020 , 10,	2
124	Gut Microbiota, Peroxisome Proliferator-Activated Receptors, and Hepatocellular Carcinoma. 2020 , 7, 271-288	6
123	Connecting the Dots Between Inflammatory Bowel Disease and Metabolic Syndrome: A Focus on Gut-Derived Metabolites. 2020 , 12,	15
122	A Role for Gut Microbiome Fermentative Pathways in Fatty Liver Disease Progression. 2020 , 9,	10
121	Gut-on-a-chip: Current progress and future opportunities. 2020 , 255, 120196	54
120	NOD2 in hepatocytes engages a liver-gut axis to protect against steatosis, fibrosis, and gut dysbiosis during fatty liver disease in mice. 2020 , 319, E305-E314	13
119	Consumption of a high energy density diet triggers microbiota dysbiosis, hepatic lipidosis, and microglia activation in the nucleus of the solitary tract in rats. 2020 , 10, 20	14
118	Beneficial effects of Chinese herbs in the treatment of fatty liver diseases. 2020 , 10, 260-267	5
117	Interactions between resveratrol and gut microbiota affect the development of hepatic steatosis: A fecal microbiota transplantation study in high-fat diet mice. 2020 , 67, 103883	8
116	Hepatic Inflammatory Response to Exogenous LPS Challenge is Exacerbated in Broilers with Fatty Liver Disease. 2020 , 10,	2
115	Gut Microbiota Dysbiosis in Patients with Biopsy-Proven Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study in Taiwan. 2020 , 12,	21
114	Paeonol ameliorates murine alcohol liver disease via mycobiota-mediated Dectin-1/IL-1 β signaling pathway. 2020 , 108, 199-214	11
113	The Liver Microbiome Is Implicated in Cancer Prognosis and Modulated by Alcohol and Hepatitis B. 2020 , 12,	5
112	Effect of Oral Administration of on Fecal and Plasma Ethanol Concentrations, Lipids and Glucose Metabolism in Wistar Rats Fed High Fructose and Fat Diet. 2020 , 12, 93-106	4

111	The correlation between intestinal mucosal lesions and hepatic dysfunction in patients without chronic liver disease. 2020 , 99, e18837	2
110	The Controversial Role of Human Gut Lachnospiraceae. 2020 , 8,	218
109	Lactobacillus plantarum NA136 ameliorates nonalcoholic fatty liver disease by modulating gut microbiota, improving intestinal barrier integrity, and attenuating inflammation. 2020 , 104, 5273-5282	25
108	Maternal hepatitis B or hepatitis C virus carrier status and long-term infectious morbidity of the offspring: A population-based cohort study. 2020 , 27, 794-799	2
107	A Candidate Drug for Nonalcoholic Fatty Liver Disease: A Review of Pharmacological Activities of Polygoni Multiflori Radix. 2020 , 2020, 5462063	0
106	Microbiome and host crosstalk: A new paradigm to cancer therapy. 2021 , 70, 71-84	8
105	Gut-organ axis: a microbial outreach and networking. 2021 , 72, 636-668	37
104	Metabolomic profiling reveals the effects of early-life lactoferrin intervention on protein synthesis, energy production and antioxidative capacity in the liver of suckling piglets. 2021 , 12, 3405-3419	1
103	Prebiotic Impacts of Soybean Residue (Okara) on Eubiosis/Dysbiosis Condition of the Gut and the Possible Effects on Liver and Kidney Functions. 2021 , 26,	11
102	Val-Val-Tyr-Pro protects against non-alcoholic steatohepatitis in mice by modulating the gut microbiota and gut-liver axis activation. 2021 , 25, 1439-1455	3
101	Mechanisms of Non-Alcoholic Fatty Liver Disease in the Metabolic Syndrome. A Narrative Review. 2021 , 10,	26
100	Wastewater treatment works change the intestinal microbiomes of insectivorous bats. 2021 , 16, e0247475	1
99	Gut microbiome and Mediterranean diet in the context of obesity. Current knowledge, perspectives and potential therapeutic targets. 2021 , 9, 100081	11
98	Subacute safety assessment of recombinant Lactococcus lactis on the gut microbiota of male Sprague-Dawley rats. 2021 , 101, 5807-5812	0
97	Current innovations in nutraceuticals and functional foods for intervention of non-alcoholic fatty liver disease. 2021 , 166, 105517	2
96	Crosstalk between PPARs and gut microbiota in NAFLD. 2021 , 136, 111255	10
95	Defining the temporal evolution of gut dysbiosis and inflammatory responses leading to hepatocellular carcinoma in Mdr2 ^{-/-} mouse model. 2021 , 21, 113	2
94	Gut Microbiota and Chemical-Induced Acute Liver Injury. 2021 , 12, 688780	6

93 Gut Microbiota And Inflammatory Disorders. **2021**,

92 Metabolomic signatures for liver tissue and cecum contents in high-fat diet-induced obese mice based on UHPLC-Q-TOF/MS. **2021**, 18, 69 5

91 Tandem mass tag-based proteomics for studying the effects of a biotechnologically produced oyster mushroom against hepatic steatosis in obese Zucker rats. **2021**, 242, 104255 0

90 Intestinal Dysbiosis and Non-Alcoholic Fatty Liver Disease. 1

89 Live Combined B. subtilis and E. faecium Alleviate Liver Inflammation, Improve Intestinal Barrier Function, and Modulate Gut Microbiota in Mice with Non-Alcoholic Fatty Liver Disease. **2021**, 27, e931143 0

88 Unhealthy Lifestyle and Gut Dysbiosis: A Better Understanding of the Effects of Poor Diet and Nicotine on the Intestinal Microbiome. **2021**, 12, 667066 15

87 Expression of Jejunal Taste Receptors in Women with Morbid Obesity. **2021**, 13, 0

86 Hepatocellular Carcinoma Immunotherapy and the Potential Influence of Gut Microbiome. **2021**, 22, 6

85 Melatonin alleviates Ochratoxin A-induced liver inflammation involved intestinal microbiota homeostasis and microbiota-independent manner. **2021**, 413, 125239 6

84 High ambient temperature exposure during late gestation disrupts glycolipid metabolism and hepatic mitochondrial function tightly related to gut microbial dysbiosis in pregnant mice. **2021**, 14, 2116-2129⁶

83 Hypoxia: The "Invisible Pusher" of Gut Microbiota. **2021**, 12, 690600 5

82 Effects of probiotic supplementation on anthropometric and metabolic characteristics in adults with metabolic syndrome: A systematic review and meta-analysis of randomized clinical trials. **2021**, 40, 4662-4673 8

81 Advances in Multi-Omics Applications in HBV-Associated Hepatocellular Carcinoma. **2021**, 8, 754709 2

80 Methionine Deficiency Affects Liver and Kidney Health, Oxidative Stress, and Ileum Mucosal Immunity in Broilers. **2021**, 8, 722567 1

79 Cancer-fighting potentials of algal polysaccharides as nutraceuticals. **2021**, 147, 110522 8

78 Therapeutic implications of probiotics in microbiota dysbiosis: A special reference to the liver and oral cancers. **2021**, 285, 120008 5

77 Electroacupuncture interventions alleviates myocardial ischemia reperfusion injury through regulating gut microbiota in rats. **2021**, 138, 104235 1

76 Links between gut microbiome composition and fatty liver disease in a large population sample. **2021**, 13, 1-22 12

75	Microbiota, NASH, HCC and the potential role of probiotics. 2017 , 38, 231-240	113
74	Links between gut microbiome composition and fatty liver disease in a large population sample.	2
73	Intestinal farnesoid X receptor signaling promotes nonalcoholic fatty liver disease. 2015 , 125, 386-402	385
72	Fecal Microbiota Taxonomic Shifts in Chinese Multiple Myeloma Patients Analyzed by Quantitative Polymerase Chain Reaction (QPCR) and 16S rRNA High-Throughput Sequencing. 2019 , 25, 8269-8280	12
71	Meta-analysis of the effects of probiotic supplementation on glycemia, lipidic profiles, weight loss and C-reactive protein in women with polycystic ovarian syndrome. 2018 , 109, 479-487	14
70	[Non-alcoholic fatty liver disease and type 2 diabetes mellitus: issues of the liver fibrosis diagnostics]. 2020 , 92, 73-78	2
69	High oleic peanuts improve parameters leading to fatty liver development and change the microbiota in mice intestine. 2020 , 64,	2
68	The Role of the Gut Microbiome in Liver Cirrhosis Treatment. 2020 , 22,	12
67	Pediatric fatty liver disease: role of ethnicity and genetics. 2014 , 20, 7347-55	47
66	Breath volatile organic compounds for the gut-fatty liver axis: promise, peril, and path forward. 2014 , 20, 9017-25	6
65	Research Progress on the Relationship between Intestinal Flora, Immune System and Glioma. 2021 , 11, 4357-4364	
64	Infectious Microecology and Immunology. 2014 , 33-57	
63	THE EFFICACY OF ERADICATION OF SMALL INTESTINAL BACTERIAL OVERGROWTH IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE. 2017 , 4, 34-41	0
62	Hepatocellular Carcinoma: Known and Emerging Risk Factors. 2018 , 09, 417-437	
61	Recent advances in understanding cross-talk between Bile Acids and Gut Microbiota. 024-034	
60	Consumption of a high energy density diet triggers microbiota dysbiosis, hepatic lipidosis, and microglia activation in the nucleus of the solitary tract in rats.	
59	Intestinal microbiota in children with obesity. Role of probiotics. 2020 , 134-142	
58	The Gut Microbiome and Liver Disease. 2020 , 1062-1068	0

57	Comparative analysis of the composition of intestinal microbiome in patients with liver diseases. 2020 , 15-22	
56	Nutrition of the critically ill - emphasis on liver and pancreas. 2012 , 1, 25-52	6
55	Probiotics and Nonalcoholic Fatty liver Disease. 2013 , 5, 129-36	37
54	Overview of the microbiota in the gut-liver axis in viral B and C hepatitis. 2021 , 27, 7446-7461	1
53	Probiotic Alleviates Oxidative Stress-Induced Liver Injury by Modulating Gut-Liver Axis in a Rat Model.. 2022 , 11,	5
52	An insight into multifunctional tool box. 2022 , Publish Ahead of Print,	
51	Oxidative Stress in Non-Alcoholic Fatty Liver Disease. 2022 , 2, 30-76	1
50	Roles of Microbiota in Cancer: From Tumor Development to Treatment.. 2022 , 2022, 3845104	0
49	Tremella fuciformis Crude Polysaccharides Attenuates Steatosis and Suppresses Inflammation in Diet-Induced NAFLD Mice. 2022 , 44, 1224-1234	0
48	Hepatoprotective Effect of Cereal Vinegar Sediment in Acute Liver Injury Mice and Its Influence on Gut Microbiota.. 2021 , 8, 798273	0
47	A new single-cell protein from Clostridium autoethanogenum as a functional protein for largemouth bass (Micropterus salmoides). 2022 ,	1
46	Image_1.jpg. 2020 ,	
45	Image_2.jpg. 2020 ,	
44	Data_Sheet_1.docx. 2019 ,	
43	Data_Sheet_1.xlsx. 2019 ,	
42	Table_1.DOCX. 2019 ,	
41	Microbiome Engineering for Metabolic Disorders. 2022 , 47-91	
40	Diet-Based Microbiome Modulation: You are What You Eat. 2022 , 1-46	

- 39 Advances in pediatric non-alcoholic fatty liver disease: From genetics to lipidomics. **2022**, 11, 221-238
- 38 The impact of dromedary camel milk on mice gut microbiota. **2022**, 65, 0
- 37 Disturbed Gut-Liver axis indicating oral exposure to polystyrene microplastic potentially increases the risk of insulin resistance.. **2022**, 164, 107273 4
- 36 Chronic exposure to polyvinyl chloride microplastics induces liver injury and gut microbiota dysbiosis based on the integration of liver transcriptome profiles and full-length 16S rRNA sequencing data.. **2022**, 155984 0
- 35 Microfluidic Organ-on-a-Chip System for Disease Modeling and Drug Development. **2022**, 12, 370 5
- 34 Interaction Between Cecal Metabolites and Liver Lipid Metabolism Pathways During Induced Molting in Laying Hens. **2022**, 13, 2
- 33 Mechanisms behind the Role of SIBO in Non-Alcoholic Fatty Liver Disease: An Interplay between Liver, Gut Microbiota and Nutrition. **2022**, 18,
- 32 Alterations in circadian rhythms aggravate Acetaminophen-induced liver injury in mice by influencing Acetaminophen metabolism and increasing intestinal permeability. **2022**, 13, 13118-13130
- 31 Chondroitin sulfate stimulates the secretion of H₂S by *Desulfovibrio* to improve insulin sensitivity in NAFLD mice. **2022**, 2
- 30 Dynamics in Circulating γ -55Proinflammatory Biomarkers for Prognostic Assessment of Patients With Advanced HCC A Substudy From the SORAMIC Trial. 1,
- 29 The role of gut microflora dysbiosis in clinical manifestation of patients with non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.. **2022**, 10, 658-667
- 28 The promising role of probiotics/prebiotics/synbiotics in energy metabolism biomarkers in patients with NAFLD: A systematic review and meta-analysis. 10,
- 27 Gut lumen-targeted oral delivery system for bioactive agents to regulate gut microbiome. **2022**, 2, 307-325 2
- 26 Polypharmacology and Polypharmacokinetics. **2022**, 647-659 0
- 25 Polysaccharide from *Salviae miltiorrhizae* Radix et Rhizoma Attenuates the Progress of Obesity-Induced Non-Alcoholic Fatty Liver Disease through Modulating Intestinal Microbiota-Related Gut-Liver Axis. **2022**, 23, 10620 0
- 24 Irritable Bowel Syndrome Symptoms in Nonalcoholic Fatty Liver Disease Patients Are an Indicator of Depression and Anxiety. Publish Ahead of Print, 0
- 23 Features of respiratory tests (hydrogen + methane), indirect liver elastometry data in COVID-19 convalescents (pilot study). **2022**, 131-144 0
- 22 Neurotensin modulation of lipopolysaccharide induced inflammation of gut-liver axis: Evaluation using neurotensin receptor agonist and antagonist. **2022**, 102297 0

- 21 Meta-analysis of the gut microbiota alterations in patients with gastric cancer in China. **2023**, 15, 100069 ○
- 20 Eco-toxicity of nano-plastics and its implication on human metabolism: Current and future perspective. **2022**, 160571 2
- 19 Gastrointestinal microbiota: A predictor of COVID-19 severity?. 28, 6328-6344 2
- 18 The Role of Microbiome in Nonalcoholic Fatty Liver Disease. **2023**, 107-118 ○
- 17 Effects of Zhishi Daozhi Decoction on the intestinal flora of nonalcoholic fatty liver disease mice induced by a high-fat diet. 12, ○
- 16 Gut Microbiota Induces Hepatic Steatosis by Modulating the T Cells Balance in High Fructose Diet Mice. ○
- 15 Butyrate producers, The Sentinel of Gut Their intestinal significance with and beyond butyrate, and prospective use as microbial therapeutics. 13, ○
- 14 Effects of Continuous LPS Induction on Oxidative Stress and Liver Injury in Weaned Piglets. **2023**, 10, 22 ○
- 13 Hydrogen inhalation ameliorates hepatic inflammation and modulates gut microbiota in rats with high-fat diet-induced non-alcoholic fatty liver disease. **2023**, 947, 175698 ○
- 12 Exploring the potential impact of probiotic use on drug metabolism and efficacy. **2023**, 161, 114468 ○
- 11 The effect of polystyrene foam in different doses on the blood parameters and relative mass of internal organs of white mice. **2022**, 30, 436-441 ○
- 10 *Saccharomyces cerevisiae* as probiotic, prebiotic, synbiotic, postbiotics and parabiotics in aquaculture: An overview. **2023**, 569, 739342 ○
- 9 Effects of dietary *Galla Chinensis* tannin supplementation on immune function and liver health in broiler chickens challenged with lipopolysaccharide. 10, ○
- 8 The Gut-Organ-Axis Concept: Advances the Application of Gut-on-Chip Technology. **2023**, 24, 4089 ○
- 7 The Effects of Probiotics on Small Intestinal Microbiota Composition, Inflammatory Cytokines and Intestinal Permeability in Patients with Non-Alcoholic Fatty Liver Disease. **2023**, 11, 640 1
- 6 Integrated Analysis of Gut Microbiome and Liver Metabolome to Evaluate the Effects of Fecal Microbiota Transplantation on Lipopolysaccharide/D-galactosamine-Induced Acute Liver Injury in Mice. **2023**, 15, 1149 ○
- 5 Diet-Induced Microbiome Impact on Heart Failure: A Double-Edged Sword. **2023**, 15, 1223 1
- 4 Gut Microbiota: A Future Clinical Magic Bullet to Manifest Pathogenic Disease in the Current Future. **2023**, 17, 51-68 ○

3	Mediterranean Diet Improves Plasma Biomarkers Related to Oxidative Stress and Inflammatory Process in Patients with Non-Alcoholic Fatty Liver Disease. 2023 , 12, 833	o
2	Assessment of Nonalcoholic Fatty Liver Disease Symptoms and GutLiver Axis Status in Zebrafish after Exposure to Polystyrene Microplastics and Oxytetracycline, Alone and in Combination. 2023 , 131,	o
1	Probiotics as Potential Therapy in the Management of Non-Alcoholic Fatty Liver Disease (NAFLD). 2023 , 9, 395	o